

KDR

Mouse Anti-Human VEGFR-2/KDR (Clone 3 (4H3)) mAb



Catalog No.	CMV012	Quantity:	100 µg
Alternate Names:	Vascular endothelial growth factor receptor 2, Kinase Insert Domain Receptor, CD309, FLK1, VEGFR		
Description:	This mouse monoclonal antibody recognizes human VEGFR-2/KDR, one of the two receptors of VEGF. VEGFR-2/KDR, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc. Mutations of this gene are implicated in infantile capillary hemangiomas, and the endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function.		
Gene ID:	3791		
Conjugate:	Unconjugated		
Specificity:	Native Human KDR/VEGFR-2		
Host:	Mouse (BALB/c)		
Isotype:	IgG1		
Immunogen:	Recombinant Human soluble extracellular KDR (D7)		
Clone:	3 (4H3)		
Formulation:	Lyophilized from PBS without preservatives.		
Purification:	Protein G		
Reconstitution:	Centrifuge vial prior to opening. Add sterile distilled water to a concentration of 0.1 -1.0 mg/mL.		
Applications:	Western Blot(WB), Flow Cytometry (FC), ELISA, Immunofluorescent (IF)Microscopy, Immunohistochemistry (IHC)		
Application Notes:	WB/ FC: use at a working dilution of 2-5 µg/mL. ELISA/ IF/ IHC: use at a working dilution of 1-5 µg/mL. Optimal dilutions should be determined by each laboratory for each application.		

Storage & Stability: Upon receipt store at -20 °C. Reconstitution, antibody is stable for two weeks at 2-8 °C or frozen aliquots for up to 6 months at -20 °C. **Avoid repeated freeze-thaw cycles.**



Figure 1: Up-regulation of VEGFR-2 in primary HUVECs by bFGF. Freshly isolated HUVECs (passage 1) were cultured in EBM. Subconfluent cultures were stimulated with VEGF (5 ng/ml) or bFGF (10 ng/ml) for 3 days. Total lysate was prepared and subjected to immunoprecipitation (anti-human VEGFR-2 (Cl.3) [Cat No CMV012] followed by Western blotting (anti-human VEGFR-2 (Cl.4) [Cat No CMV016]).

Figure 2: FACS analysis of VEGFR-2/KDR expression in human primary dermal microvascular and umbilical vein endothelial cells.



NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

